Keystone Symposia Conference | The Molecular Basis of Schizophrenia and Bipolar Disorder

Meeting Program

To view program in "24 hour" time (international) click here.

Friday, March 6
3:00 - 7:30 PM	Registration	Longs Peak Foyer
6:30 - 7:30 PM	Refreshments	Longs Peak Foyer
7:30 - 8:30 PM	Keynote Address Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	Thomas R. Insel, National Institute of Mental Health, USA The Molecular Basis of Schizophrenia and Bipolar Disorder: What do We Know? What Do We Need?
Saturday, March 7
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Genome-Wide Studies of Disease-Related Variation Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	Mark J. Daly†, Harvard Medical School, USA Overview of Genome-Wide Association Studies, Lessons from other Diseases, and Application to Psychiatric Disorders
	Pamela Sklar, Harvard Medical School, Massachusetts General Hospital, USA Genome-Wide Association Studies of Bipolar Disorder
	Patrick F. Sullivan, University of North Carolina, USA Genome-Wide Association Studies of Schizophrenia
	Jonathan Sebat, Cold Spring Harbor Laboratory, USA Analysis of Genome Copy Number Variation in Psychiatric Disease
	Short Talk(s) to be Chosen from Abstracts,
Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
8:00 - 11:00 AM	Epigenetic Mechanisms in Human Biology Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	Stephen T. Warren, Emory University School of Medicine, USA Molecular Basis of Neurodevelopmental Disorders

	Speaker to be Announced,
	Guoping Fan, University of California, Los Angeles, USA Epigenetic Regulation in Neuronal Survival and Brain Development

	Michael E. Zwick, Emory University School of Medicine, USA A Genome Sequencing Center in Every Lab: Harnessing Next-Generation Sequencing Technology to Identify Autism Susceptibility Loci
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM- 1:00 PM	Poster Setup	Quandary Peak
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Quandary Peak
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Clinical Epidemiology and Etiology Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	Peter B. Jones, Cambridge University, UK Epidemiology and Risk Factors, Shared or Not?
	Nick J. Craddock, Cardiff University School of Medicine, UK The Boundaries of the Phenotypes
	Christopher Ross, Johns Hopkins University School of Medicine, USA Insights from Neurodegeneration: Approaches for Psychiatric Disease

Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
5:00 - 6:10 PM	Monogenic Neurodevelopmental Disorders: Rett Syndrome Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	David Katz, Case Western Reserve University School of Medicine, USA Mecp2 and Rett Syndrome

	Xinyu Zhao, University of New Mexico, USA Methyl-CpG Binding Proteins in Neurogenesis and Autism Spectrum Disorders
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Quandary Peak
Sunday, March 8
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Genes and Pathways Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	David Porteous, University of Edinburgh, UK Genetic and Molecular Investigation of DISC1
	Hongjun Song, Johns Hopkins University School of Medicine, USA DISC1 and Neuronal Development
	Daniel R. Weinberger, NIMH/NIH, USA Genetic and Molecular Studies of NRG1/ErbB4
	Speaker to be Announced, Novel Susceptibility Genes Emerging from Genetic Studies
	Short Talk(s) to be Chosen from Abstracts,
Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
8:00 - 11:00 AM	Autism Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	Daniel H. Geschwind, University of California, Los Angeles, USA Identification of Genomic Loci Involved in Autism
	David H. Ledbetter, Emory University School of Medicine, USA Copy-Number Variants in Autism
	* Janine M. LaSalle, University of California, Davis, USA Epigenetic Etiologies of Autism Spectrum Disorders

	Speaker to be Announced,
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM- 1:00 PM	Poster Setup	Quandary Peak
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Quandary Peak
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Genes and Pathways II Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	Marc G. Caron, Duke University Medical Center, USA Akt/GSKbeta Signaling and Behavioral Abnormalities
	Li-Huei Tsai, Massachusetts Institute of Technology, USA Signaling Pathways Linking Brain Development and Schizophrenia
	Speaker to be Announced, Novel Susceptibility Genes Emerging from Genetic Studies
	Short Talk to be Chosen from Abstracts,
Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
5:00 - 7:00 PM	Imprinting Disorders Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	* Arthur L. Beaudet, Baylor College of Medicine, USA Molecular Basis of Angelman Syndrome
	Laura Herzing, Children's Memorial Research Center, USA DNA Methylation and Imprinting Disorders
	Edwin J. Weeber, University of South Florida, USA Synaptic Plasticity Defects in Angelman Syndrome
	Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Quandary Peak
Monday, March 9
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Evolution and Development of the Brain Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	Fred H. Gage, The Salk Institute for Biological Studies, USA Neurogenesis and Relevance of Non-Coding RNAs
	Bruce Lahn, University of Chicago, USA Fast-Evolving Genes of the Human Brain

	Speaker to be Announced,
	Judith L. Rapoport, NIMH, USA Brain Development in Childhood Onset Schizophrenia
	Short Talk(s) to be Chosen from Abstracts,
Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
8:00 - 11:00 AM	Psychiatric Epigenetics Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	Art Petronis, Centre for Addiction and Mental Health, Canada Epigenomics of Major Psychosis
	Erminio Costa, University of Illinois, Chicago, USA DNA Methylation in Schizophrenia

	Speaker to be Announced,
	* Michael Meaney, McGill University, Canada Maternal Regulation of DNA Methylation and Vulnerability for Psychopathology
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM-	On Own for Lunch
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Chemical Biology and Therapeutic Strategies Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Grays Peak
	John R. Kelsoe, University of California, San Diego, USA Perspectives in Pharmacogenomics
	Christopher P. Austin, National Human Genome Research Institute, USA Small Molecule Screens in Schizophrenia and Bipolar Disorder
	Edward M. Scolnick, MIT Broad Institute, USA Closing Talk: Towards Mechanism Based Drug Development in Bipolar Disorder and Schizophrenia: Using Genetics and Neurobiology to Drive Novel Screening Methods
Following Session is for Epigenetic Basis of Neurodevelopmental Disorders (X2)
5:00 - 7:00 PM	Lessons, Conclusions, and Perspectives Registered attendees for this meeting can view Abstracts for this session starting on 02/06/2009	Longs Peak
	Peter A. Jones, University of Southern California, USA Epigenetic Regulation in Cancer
	Jeffrey M. Besterman, Methylgene Inc., Canada Epigenetic Therapy of Neurodegenerative Diseases

	Bing Ren, University of California, San Diego, USA Talk Title to be Determined

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
8:00 - 11:00 PM	Entertainment	Quandary Peak
Tuesday, March 10
	Departure
*=Session Chair †=Speaker invited, not yet responded.

We gratefully acknowledge the companies that provide Keystone Symposia with additional meeting support, including marketing and advertising...

Click here to view these companies

This meeting brings together experts in a range of disciplines, including genetics, neurobiology, cell and developmental biology, psychiatry, and chemical biology to discuss the molecular bases of bipolar disorder and schizophrenia. The time is opportune, since new methods in genetics are identifying plausible candidate genes, which can be studied by sophisticated techniques of cell biology and neuroscience, in both laboratory and clinical settings. Bipolar disorder and schizophrenia are severe psychiatric syndromes characterized by mood and cognitive disorders and psychosis. Both genetic and environmental factors are believed to contribute. New findings in genetics and neuroscience will likely help redefine the phenotypes and make possible the development of new therapeutic targets. Among the topics to be explored include emerging data from genetics implicating new genes and genetic variation in disease; the current status of the epidemiology, including environmental factors, and boundaries of the disorders; the genetics and neurobiology of several current candidate genes and pathways; and the relevance of advances in neurogenesis, fast-evolving brain genes, and cerebral circuitry development. Finally, prospects for new approaches to therapeutics will be covered. The overall goal of this meeting is to integrate molecular studies across basic and clinical disciplines and facilitate the development of new approaches.

The Molecular Basis of Schizophrenia and Bipolar Disorder (X1)